The cost for Otezla oral tablet (10 mg-20 mg-30 mg) is around $889 for a supply of 27 tablets

*Hot summer ad wars: Celgene launches Otezla DTC into crowded psoriasis drug market

by Beth Snyder Bulik | 

Jul 6, 2015 8:37am

 * https://www.fiercepharma.com/dtc-advertising/hot-summer-ad-wars-celgene-launches-otezla-dtc-into-crowded-psoriasis-drug-market

ShareFacebookTwitterLinkedInEmailPrint

Celgene's ($CELG) Otezla is the newest entrant in what is shaping up to be a summer throwdown among psoriasis drugmakers. Not surprisingly, every company's got its own strategy.

Otezla "Show More of You" TV Spot

The psoriasis-fighting TV spot for Otezla, which was approved for plaque psoriasis in September, began June 14 with spending topping $5.6 million through the first two weeks ending July 1, according to iSpot.tv, which tracks TV ad metrics in real time. The "Show More of You" TV spot aired more than 1,600 times, ranging from 70-100 placements per day, on both cable and broadcast.

Otezla joined Johnson & Johnson's ($JNJ) Stelara, whose TV campaign featuring model CariDee English had been running since June 1. J&J spent $2.1 million for the month on 724 national airings for its ad, according to iSpot. Not to be left out, AbbVie's ($ABBV) blockbuster Humira launched its own psoriasis TV onslaught, spending $1 million in just one week on 988 airings--a whopping 130-150 placements per day, on average.

Strategic blitz or coincidence? You decide. But, ahem, the Humira campaign using already-existing creative launched on the exact same day as Otezla's DTC, according to iSpot data.

Taking a different tack, Amgen ($AMGN) and Pfizer's ($PFE) Enbrel halted its psoriasis TV spot in mid-May, and used June to highlight the drug for psoriatic arthritis, the other common indication for these drugs. Golfer Phil Mickelson starred in two different spots still hawking for Enbrel.

Head spinning yet? Imagine what it's like to be a treating physician or potential patient. And they're not likely to get a marketing break anytime soon with the next generation of drugs already out of the gate.

Novartis ($NVS), whose Cosentyx won psoriasis approval in January, has yet to fire an aggressive pitch, although the drugmaker has said it expects the drug to top out at sales of $4 billion to $5 billion. Think it will get there without aggressive marketing? Not likely.

Meanwhile, Boehringer Ingelheim recently entered Phase III trials with its IL-23, meeting Amgen and AstraZeneca's ($AZN) brodalumab and Eli Lilly's ($LLY) ixekizumab already in that final phase--and looking to finish next behind Cosentyx in the new IL-17 inhibitor category.

Oh, but wait--there's more. Johnson & Johnson's guselkumab is further behind, but also making its way along the approval chain.

Celgene, which declined comment for this story, had projected Otezla sales at $1.5 billion to $2 billion in 2017, but it's faced a series of setbacks lately. The drug was turned down for recommendation by the National Institute for Health and Care Excellence (NICE) in England, following the news that Germany's cost gatekeeper IQWiG didn't see added benefits for Otezla compared with treatments already on the market.

The Tufts Center for the Study of Drug development (CSDD) is funded in part by unrestricted grants from pharmaceutical and biotechnology firms

  Having  a fox guard the chicken coop 

The Tufts Center for the Study of Drug development (CSDD) is funded in part by unrestricted grants from pharmaceutical and biotechnology firms, as well as companies that provide related services (e.g., contract research, consulting, and technology firms) to the research-based industry. Tufts CSDD's financial disclosure statement can be found here: http://csdd.tufts.edu/about/financial_disclosure. The authors and Tufts CSDD did not receive any external funding to conduct this study. The R&D cost and expenditure data for individual compounds and companies are proprietary and cannot be redistributed. Other data used were obtained from subscription databases and the Food and Drug Administration (FDA) and other websites


U try to look at the  financial disclosure website  and  this is  what i get 

We couldn't find the page you were looking for. This is either because:

• There is an error in the URL entered into your web browser. Please check the URL and try again.
• The page you are looking for has been moved or deleted.

You can return to our homepage by clicking here, or you can try searching for the content you are seeking by clicking here.

The Tufts Center for the Study of Drug development (CSDD) study is widely sited for  talking about the   costs of bringing a new medication to the market

costly VS cheap drugs for ring worm treatment of tinea pedis, tinea cruris, and tinea corporis

CONCLUSION — Luliconazole (Luzu Cream, 1%) appears to be moderately effective for treatment of tinea pedis and tinea cruris infections. There is no evidence that it is more effective than other topical antifungals that are available generically or over the counter at a much lower cost.

The cost for luliconazole topical topical cream 1% is around $176 for a supply of 60 grams,

Where are the Indian feminists?

90 per cent people favour free rides for women in metros and buses: AAP

How in the world can there be such a big price differential between the U.S. and other countries? Viva La mehico!

To fight high drug prices, Utah will pay for public employees to go fill prescriptions in Mexico
To fight high drug prices, Utah will pay for public employees to go fill prescriptions in Mexico
(Associated Press file photo ) U.S. Customs and Border Protection agents stand at the San Ysidro Port of Entry in San Diego in 2011. The nation's busiest border crossing connects San Diego and Tijuana, Mexico. To save money on drugs, Utah is offering to cover travel expenses for public employees willing to go fill certain high-cost prescriptions in Tijuana.
97

By Erin Alberty
 ·
Published: October 28, 2018
Updated: October 29, 2018
Amid a flurry of national proposals to bring exorbitant U.S. drug prices in line with other countries’ charges, one Utah insurer has a different option for patients:

Pay them to go to Mexico.

PEHP, which covers 160,000 public employees and family members, is offering plane tickets to San Diego, transportation to Tijuana, and a $500 cash payout to patients who need certain expensive drugs for multiple sclerosis, cancer and autoimmune disorders.


“That money is pretty small in comparison to the difference between U.S. prices and Mexico prices,” said Travis Tolley, clinical operations director for PEHP.

The insurer rolled out its “pharmacy tourism” option this fall in response to state legislation requiring state employees’ insurance plans to offer “savings rewards,” or cash incentives, to patients who choose cheaper providers.

PEHP is offering pharmacy tourism benefits for about a dozen drugs for which the price disparity between countries is vast. For example, Avonex, which treats MS, costs about $6,700 for a 28-day supply in the U.S., but about $2,200 through PEHP’s contracted clinic in Tijuana.

For three months’ supply — the maximum allowed under the program — the savings of $13,500 more than covers the $500 reward and transportation, typically less than $300 per person.

“Why wouldn’t we pay $300 to go to San Diego, drive across to Mexico and save the system tens of thousands of dollars?” asked state Rep. Norman Thurston, R-Provo, who sponsored the legislation calling for incentives. “If it can be done safely, we should be all over that.”


Patients who participate will fly to San Diego, be driven through a priority lane at the border crossing and arrive at a clinic, which PEHP director Chet Loftis described as “top-notch,” comparable to a Mayo or Cleveland clinic in the United States.

Medical tourism is not new; PEHP itself has previously offered coverage for out-of-country medical procedures. But without the cash incentives, patients haven’t used that option, Loftis said. Now that clients are eligible for up to $3,900 a year in reward payments for trips to Tijuana for procedures and drugs, Loftis said he hopes more will participate.

“It makes sense to not only pay for the cost,” he said, “but also to provide an incentive.”

The pharmacy tourism incentive is launching as Trump administration officials are focusing on the disparity between drug prices in the United States and in other countries. On Thursday, President Donald Trump announced a proposal focusing on the price of drugs under Medicare Part B, which covers cancer drugs and other drugs given to patients in hospitals. Federal law at present forbids Medicare from negotiating lower drug prices — a rule that Congress has resisted changing — but Trump proposed a trial that would limit Medicare payments for certain Part B drugs to prices closer to what other countries negotiate.

The experiment would apply only to half of Medicare recipients, in select areas of the country, and to some doctor-administered drugs.

For other insurers, like PEHP, the border may remain the closest shot at savings.


“When you start looking at the list at these higher-priced drugs people are taking, you think, ‘How in the world can there be such a big price differential between the U.S. and other countries? What’s going on?’” Thurston said. "Why wouldn’t we fly our employee to Mexico?”

TRAVELING FOR DRUGS
Here are the drugs that qualify for Utah’s pharmacy tourism benefit, and the illnesses they are generally used to treat.
Ampyra, multiple sclerosis The cost for Ampyra oral tablet, extended release 10 mg is around $2,819 for a supply of 60 tablets
Aubagio, multiple sclerosis
The cost for Aubagio oral tablet 7 mg is around $7,125 for a supply of 28
Avonex, multiple sclerosis
 The cost for Avonex intramuscular powder for injection 30 mcg is around $7,239 for a supply of 4 powder for injection, depending on the pharmacy you visit
Copaxone, multiple sclerosis
 The cost for Copaxone subcutaneous solution (20 mg/mL) is around $7,436 for a supply of 30 milliliters
Enbrel, autoimmune disorders, such as psoriatic and rheumatoid arthritis
The cost for Enbrel   subcutaneous kit 25 mg is around $2,709 for a supply of 4 kits

Firdapse is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder.
Firdapse
The cost for Firdapse oral tablet 10 mg is around $21,461 for a supply of 120 tablets, 
Forteo, osteoporosis
 The cost for Forteo subcutaneous solution (600 mcg/2.4 mL) is around $3,586 for a supply of 2.4 milliliters

Gilenya, multiple sclerosis

The cost for Gilenya oral capsule 0.5 mg is around $8,580 for a supply of 30 capsules

Humira, arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis

The cost for Humira subcutaneous kit (10 mg / 0.1 mL) is around $5,410 for a supply of 2
Orencia, rheumatoid arthritis

The cost for Orencia intravenous powder for injection 250 mg is around $1,166 for a supply of 1 powder for injection

Otezla, psoriasis

The cost for Otezla oral tablet (10 mg-20 mg-30 mg) is around $889 for a supply of 27 tablets
Stelara, plaque psoriasis and psoriatic arthritis

The cost for Stelara intravenous solution (5 mg / mL) is around $1,679 for a supply of 26 milliliters


Tecfidera, psoriasis

The cost for Tecfidera oral delayed release capsule 120 mg is around $1,910 for a supply of 14 capsules

Zytiga, prostate cancer

The cost for abiraterone oral tablet 250 mg is around $3,275 for a supply of 120 tablets

Make a borewell cap with a small Hole may be 2 inches diameter th

Fatehveer death case: All that was needed to prevent this tragedy — A Rs 500 borewell cap

Soon after the body of two-year-old Fatehveer was pulled out of a 125-ft bore well in an over 100-hr rescue operation that many said was botched, Punjab Chief Minister Capt. Amarinder Singh on Tuesday asked the deputy commissioners of all districts to get open bore wells closed.

 CAP to close the mouth of a borewell costs not more than Rs 500-700, according to agriculture equipment manufacturers. But in Punjab, several borewells lie open due to a superstition among some farmers — that the mouth of a borewell should not be closed as they consider water to be ‘khwaja pir’ (water god).

India’s scholarship scandal why from Gulf news

 Why the Indian media not giving out this news first ?

Shame on people in the  education sector.
Just having  a clean PM is not enough every Indian  has to feel bribery is bad and stop doing it

India’s scholarship scandal:

 How officials, bankers cheated poor students

Government officials, private institutions and banks have been colluding, finds report

Published:  June 15, 2019 16:02

IANS

  

 cash-3829601_1920

100 Rupee banknotes. For illustrative purposes only.

Image Credit: Agency

New Delhi: Initial investigations by the Central Bureau of Investigation (CBI) into the multi-million scholarship scam reveals a deep-rooted nexus between government officials, private institutions and public sector banks to siphon-off funds meant for the students who need financial aid the most.

Sources in CBI revealed to IANS that the scam that affected the scholarship fund meant for children below the poverty line (BPL) was spread across Himachal Pradesh, Haryana and Punjab.

Though the scope of the investigation pursued by CBI's Shimla branch is limited to this region, sources said that the scam is widespread and similar complaints have been made in Uttarakhand, Uttar Pradesh and other parts of the country.

"In the interest of the poor and SC/ST [schedule cast/schedule tribe] students, the agency can take up more such cases if the matter is recommended to us by other states," said a highly-placed source in the CBI.

The agency's investigation revealed that institutions like Lovely Professional University and Karnataka University established centres in different states, including Himachal Pradesh, where documents of SC/ST and BPL students were collected but admissions not granted. Later, with the connivance of officials of the Education Department and banks, fake bank accounts were opened on the basis of genuine documents (and addresses) secured by the centres.

For instance, almost 250 students of village Dehri in Himachal's Kangra district had applied at these centres, which took the documents of these students but did not give them admission.

Subsequently, a large number of fake accounts were opened in the State Bank of India and the Allahabad Bank on the basis of documents submitted by the students and the bank officials did not verify the account holders, facilitating the con men siphoning off the scholarship money.

Last month, the CBI conducted raids at multiple locations in northern India in the Rs 2.5 billion scholarship scam related to pre- and post-matric scholarship scheme. The CBI sleuths carried out raids in 22 educational institutes across Punjab, Himachal Pradesh, Chandigarh and Haryana.

Besides the CBI, police in Uttarakhand and Uttar Pradesh are also investigating scams related to scholarships where officials of the Education Department and private institutions have been found to be hand in glove. In Uttar Pradesh, the scam relates to the Minority Department, where scholarships of poor Muslim students were fraudulently siphoned-off by corrupt officials.